Discovery Life Sciences

OpenAI introduced GPT-Rosalind life sciences, a specialized AI model designed to accelerate life sciences research, drug discovery, and translational medicine. The model combines advanced reasoning with tool integration to help scientists work through complex research workflows faster.

SAS published 15 predictions for AI in health care and life sciences on April 2, 2026, covering clinical decisions, drug discovery, rural access, and pharmaceutical manufacturing. Experts said leading organizations will treat data and AI as core infrastructure in 2026.

Discovery Life Sciences and Mindpeak have partnered to integrate AI-powered digital image analysis into cancer biomarker testing for global clinical trials, targeting inconsistent pathologist interpretation.